Cost-Effectiveness Analysis of Tisagenlecleucel in the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia in Children and Young Adults in Spain.
Josep-María RiberaAlejandra de Andrés SaldañaNuria García-MuñozJoana GostkorzewiczDiana Martínez LlinàsCristina Díaz de HerediaPublished in: ClinicoEconomics and outcomes research : CEOR (2020)
Tisagenlecleucel would represent a cost-effective intervention for the treatment of children and young adults with r/r ALL in Spain.